Racial and Aging Effects of Acute Antioxidant Supplementation
NCT ID: NCT02157207
Last Updated: 2015-06-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
93 participants
INTERVENTIONAL
2014-04-30
2015-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Our central hypothesis is that acute antioxidant supplementation will improve arterial function at rest and during exercise in African Americans without an impact of age, whereas aging will modify these effects in Caucasians.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effects of Dietary Antioxidants on Cardiovascular Risk Factors
NCT00756405
The Effect of Antioxidants on Skin Blood Flow-BH4
NCT03680573
Study of Supplement's Antioxidant Properties That Contains Natural Extracts
NCT02837107
Investigating a Natural Antioxidant Food Product on Oxidative Stress in Recreationally Active Participants
NCT04959006
Oxidative Stress and Nutritional Supplementation Intervention Study
NCT01234506
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
PREVENTION
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo
Placebo will be ingested in front of laboratory personnel in two doses, separated by 30 minutes to increase absorption, consumed 90 and 60 minutes before the testing protocol. Placebo microcrystalline cellulose capsules will be of similar taste, color and appearance.
Antioxidant
Comparison of antioxidant supplementation with a placebo. Effects of race and age and race in repsonse to the supplementation will be evaluated.
Placebo
Comparison of antioxidant supplementation with a placebo. Effects of race and age and race in repsonse to the supplementation will be evaluated.
Antioxidant
Supplementation will be ingested in front of laboratory personnel in two doses, separated by 30 minutes to increase absorption, consumed 90 and 60 minutes before the testing protocol. The first dose will consist of 300 mg of α-lipoic acid, 500 mg of vitamin C, and 200 IU of vitamin E, and the second dose will be 300 mg of α-lipoic acid, 500 mg of vitamin C, and 400 IU.
of vitamin E.
Antioxidant
Comparison of antioxidant supplementation with a placebo. Effects of race and age and race in repsonse to the supplementation will be evaluated.
Placebo
Comparison of antioxidant supplementation with a placebo. Effects of race and age and race in repsonse to the supplementation will be evaluated.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Antioxidant
Comparison of antioxidant supplementation with a placebo. Effects of race and age and race in repsonse to the supplementation will be evaluated.
Placebo
Comparison of antioxidant supplementation with a placebo. Effects of race and age and race in repsonse to the supplementation will be evaluated.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* General Good health
* Without diagnosed atherosclerotic disease
* Without metabolic or inflammatory disease
* Do not use antioxidant vitamin supplementation
* Do not use anti-inflammatory medication within last 2 weeks
* Do not use steroidal substances within past 2 weeks
Exclusion Criteria
* Severe obesity (BMI\>40 kg/m2)
* Blood pressure greater than 140/90 mmHg
* Diabetes (fasting glucose \>110 mg/dl)
* Hyperlipidemia (total cholesterol \>240 mg/dl)
* Inflammatory disease (rheumatoid arthritis, systemic lupus erythematosus, etc)
* Diagnosed atherosclerotic heart disease
* Diagnosed cardiac arrhythmia
* Bacterial, viral or upper respiratory infection within past 1 month
* Bleeding disorder
* Anticoagulant medication
* Pregnant women
18 Years
75 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Illinois at Chicago
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Bo Fernhall
Dean
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bo Fernhall, Ph.D.
Role: PRINCIPAL_INVESTIGATOR
University of Illinois at Chicago
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Illinois - Chicago
Chicago, Illinois, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2013-0980
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.